APLS vs FAST · rev $781.4M vs P/E 43, rev $7.55B
Apellis Pharmaceuticals Inc (APLS) versus Fastenal Company (FAST) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
Fastenal Company (FAST) is a industrial distribution company listed on US.
Latest reported APLS revenue for 2024-12-31 was $781.4M. Net income was -$197.9M. Revenue was up 97.0% from 2023-12-31 to 2024-12-31. APLS currently screens at market cap $2.29B.
Latest reported FAST revenue for 2024-12-31 was $7.55B. Net income was $1.15B. Revenue was up 2.7% from 2023-12-31 to 2024-12-31. FAST currently screens at market cap $49.48B and trailing P/E 43.1.
APLS currently screens at market cap $2.29B. FAST currently screens at market cap $49.48B and trailing P/E 43.1.
Not investment advice. Open the APLS and FAST stock pages for the full models.
Not investment advice.